



18 MARCH

2.30 P.M.
ROOM A102
POVO 2

NADIA MENSALI

OSLO UNIVERSITY HOSPITAL (UOH)
NORWAY

Immunotherapeutic strategies for solid tumours: discovery and validation of novel targets for CAR and TCR adoptive cell transfer (ACT)

In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, significantly improving outcomes for many patients. However, despite their remarkable efficacy, a substantial proportion of patients do not respond to ICIs or become resistant. One major limitation is the insufficient presence of tumour-specific effector T cells within the tumour microenvironment, leading to a weak endogenous antitumour response.

Advancement in T cell engineering techniques has led to the development of immunotherapy based on adoptive cell transfer (ACT), which consists in the infusion of tumour-reactive T cells. Several ACT approaches, including T-cell based therapies genetically modified to express chimeric antigen receptor (CAR) and T cell receptor (TCR), have emerged, offering new therapeutic options for the treatment of haematological and solid cancers.

CIBIO EXTERNAL SEMINAR



UNIVERSITÀ
DI TRENTO

Dipartimento di
Biologia Cellulare, Computazionale e Integrata - CIBIO



DEPARTMENT OF CELLULAR, COMPUTATIONAL
AND INTEGRATIVE BIOLOGY - CIBIO
VIA SOMMARIVE, 9
38123 - POVO (TN)
COMUNICAZIONE.CIBIO@UNITN.IT